BALPHARMA

Bal Pharma Share Price

₹135.15 +4.27 (3.26%)

21 Nov, 2024 14:16

SIP TrendupStart SIP in BALPHARMA

Start SIP

Performance

  • Low
  • ₹129
  • High
  • ₹137
  • 52 Week Low
  • ₹89
  • 52 Week High
  • ₹158
  • Open Price₹131
  • Previous Close₹131
  • Volume53,375

Investment Returns

  • Over 1 Month + 3.83%
  • Over 3 Month + 17.64%
  • Over 6 Month + 31.66%
  • Over 1 Year + 21.92%
SIP Lightning

Smart Investing Starts Here Start SIP with Bal Pharma for Steady Growth!

Invest Now

Bal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.1
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 215
  • P/B Ratio
  • 3.1
  • Average True Range
  • 6.69
  • EPS
  • 4.81
  • Dividend Yield
  • 0.9
  • MACD Signal
  • -1.92
  • RSI
  • 57.62
  • MFI
  • 75.66

Bal Pharma Financials

Bal Pharma Technicals

EMA & SMA

Current Price
₹135.15
+ 4.27 (3.26%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹124.08
  • 50 Day
  • ₹125.91
  • 100 Day
  • ₹124.17
  • 200 Day
  • ₹118.39

Resistance and Support

128.68 Pivot Speed
  • R3 145.64
  • R2 139.25
  • R1 135.07
  • S1 124.50
  • S2 118.11
  • S3 113.93

What's your outlook on Bal Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bal Pharma has an operating revenue of Rs. 324.34 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 3% needs improvement, ROE of 10% is good. The company has a debt to equity of 52%, which is bit higher. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 11% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-12 Quarterly Results, ESOP & A.G.M.
2024-05-28 Audited Results & Final Dividend
2024-02-12 Quarterly Results
2023-11-08 Quarterly Results & ESOP

Bal Pharma F&O

Bal Pharma Shareholding Pattern

50.86%
0.13%
33.15%
15.86%

About Bal Pharma

  • NSE Symbol
  • BALPHARMA
  • BSE Symbol
  • 524824
  • Managing Director
  • Mr. Shailesh D Siroya
  • ISIN
  • INE083D01012

Similar Stocks to Bal Pharma

Bal Pharma FAQs

Bal Pharma share price is ₹135 As on 21 November, 2024 | 14:02

The Market Cap of Bal Pharma is ₹215.2 Cr As on 21 November, 2024 | 14:02

The P/E ratio of Bal Pharma is 28.1 As on 21 November, 2024 | 14:02

The PB ratio of Bal Pharma is 3.1 As on 21 November, 2024 | 14:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23